1
|
Baxter SM, Bjørge T, Bjerkvig R, Cardwell C, Engeland A, Eriksson J, Habel L, Igland J, Klungsøyr K, Lunde A, Miletic H, Olesen M, Pottegård A, Reutfors J, Sharifian MJ, Linder M, Hicks B. Use of psychotropic medications among glioma patients in Denmark, Norway, Sweden, and Wales. J Neurooncol 2025:10.1007/s11060-025-04996-0. [PMID: 40208515 DOI: 10.1007/s11060-025-04996-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2025] [Accepted: 03/01/2025] [Indexed: 04/11/2025]
Abstract
PURPOSE Glioma patients often suffer from psychiatric and neurological conditions. However, little is known about the patterns of use of psychotropic drugs pre- and post-glioma diagnosis. Therefore, we assessed temporal patterns of psychotropic prescriptions among glioma patients, compared to an age and sex matched comparison cohort in four European countries. METHODS Incident gliomas were identified in Wales from the Secured Anonymized Information Linkage Databank (2005-2016) and population-based registries in Denmark (2001-2016), Norway (2006-2019), and Sweden (2008-2018). From each data source, a cancer-free comparison cohort was matched to the glioma cases by age and sex. We calculated rates of new psychotropic prescriptions and any psychotropic prescriptions during the 2 years prior to and post glioma diagnosis. Analyses were stratified by histological subtypes and subclasses of psychotropic medications. RESULTS We identified 16,007 glioma patients. The rate of new psychotropic drug use increased from 7 months before diagnosis, peaking around the month of glioma diagnosis (with peak rates ranging from 227 to 753 new psychotropic drugs per 1000 person-months). New use remained substantially higher among glioma patients than comparators throughout the 2-year follow-up period after glioma diagnosis, though rates of new use continued to decline throughout. New use was largely driven by antiepileptics, anxiolytics, hypnotics, and sedatives. Patterns were similar when analyses were stratified by histological subtype. CONCLUSION Psychotropic drug use among glioma patients was high, and elevations observed around the time of cancer diagnosis, largely driven by antiepileptics, anxiolytics, hypnotics, and sedatives, are likely associated with the consequences of the disease.
Collapse
Affiliation(s)
- Sarah M Baxter
- Centre for Public Health, Queen's University Belfast, Belfast, BT12 6BA, Northern Ireland
| | - Tone Bjørge
- Department of Global Public Health and Primary Care, University of Bergen, N-5020, Bergen, Norway
- Cancer Registry of Norway, Norwegian Institute of Public Health, NO-0304, Oslo, Norway
| | - Rolf Bjerkvig
- Department of Biomedicine, University of Bergen, N-5020, Bergen, Norway
| | - Christopher Cardwell
- Centre for Public Health, Queen's University Belfast, Belfast, BT12 6BA, Northern Ireland
| | - Anders Engeland
- Department of Global Public Health and Primary Care, University of Bergen, N-5020, Bergen, Norway
- Department of Chronic Diseases, Norwegian Institute of Public Health, N-0213, Oslo, Norway
| | - Julia Eriksson
- Centre for Pharmacoepidemiology, Karolinska Institutet, 171 76, Stockholm, Sweden
| | - Laurel Habel
- Division of Research, Kaiser Permanente Northern California, Oakland, CA, 94588, USA
| | - Jannicke Igland
- Department of Global Public Health and Primary Care, University of Bergen, N-5020, Bergen, Norway
- Department of Health and Caring Sciences, Western Norway University of Applied Sciences, 5020, Bergen, Norway
| | - Kari Klungsøyr
- Department of Global Public Health and Primary Care, University of Bergen, N-5020, Bergen, Norway
- Division of Mental and Physical Health, Norwegian Institute of Public Health, N-0213, Oslo, Norway
| | - Astrid Lunde
- Department of Global Public Health and Primary Care, University of Bergen, N-5020, Bergen, Norway
| | - Hrvoje Miletic
- Department of Biomedicine, University of Bergen, N-5020, Bergen, Norway
| | - Morten Olesen
- Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, 5230, Odense, Denmark
| | - Anton Pottegård
- Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, 5230, Odense, Denmark
| | - Johan Reutfors
- Centre for Pharmacoepidemiology, Karolinska Institutet, 171 76, Stockholm, Sweden
| | - Mohammad Jalil Sharifian
- Department of Global Public Health and Primary Care, University of Bergen, N-5020, Bergen, Norway
| | - Marie Linder
- Centre for Pharmacoepidemiology, Karolinska Institutet, 171 76, Stockholm, Sweden
| | - Blánaid Hicks
- Centre for Public Health, Queen's University Belfast, Belfast, BT12 6BA, Northern Ireland.
- Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark, 5230, Odense, Denmark.
| |
Collapse
|
2
|
Wright ML, Miller H, Vera E, Acquaye‐Mallory AA, Chavis B, Choi A, Grajkowska E, Kunst T, Johnson M, Karim Z, McIver B, Managoli M, Reyes J, Armstrong TS, King AL. Social Determinants of Health Predict Sleep-Wake Disturbances Among Patients Living With Primary Brain Tumors: A Cross-Sectional Analysis. Cancer Med 2025; 14:e70693. [PMID: 39953810 PMCID: PMC11829114 DOI: 10.1002/cam4.70693] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2024] [Revised: 01/15/2025] [Accepted: 02/05/2025] [Indexed: 02/17/2025] Open
Abstract
INTRODUCTION Sleep disturbance (SD) and sleep-related impairment (SRI) significantly impact the lives of primary brain tumor (PBT) patients. We aimed to describe the prevalence of SD and SRI in this population, determine the reliability of the PROMIS-SD and PROMIS-SRI instruments, and identify predictive factors to support the development of targeted interventions for at-risk individuals. METHODS This cross-sectional study evaluated SD and SRI in PBT patients enrolled in a Natural History Study who completed 1-year follow-up questionnaires (N = 229). Demographic, clinical, and socioeconomic data were analyzed to identify factors associated with SD and SRI. Descriptive statistics were used to report the prevalence of sleep problems, and linear regression analysis was conducted to identify predictive factors. The reliability of sleep-related instruments was calculated using Cronbach's alpha. RESULTS Fifteen percent of PBT participants reported clinically significant SD and 20% reported clinically significant SRI, which were associated with financial toxicity (p < 0.001), being unemployed (p ≤ 0.02), and taking psychotropic medication (p ≤ 0.002). Good internal consistency was demonstrated by the SD (0.923) and SRI (0.925) questionnaires in this population. CONCLUSIONS In this study, social factors such as financial toxicity and employment status were associated with SD and SRI. Psychotropic medications also impacted SD and SRI in PTB survivors, but less so than financial toxicity. Social factors and other medications may impact sleep more strongly in PBT survivors than their previous treatment courses. IMPLICATIONS FOR CANCER SURVIVORS SD and SRI can be impacted by multiple factors, including those not related to PBT treatment, which should be considered by their providers.
Collapse
Affiliation(s)
- Michelle L. Wright
- Neuro‐Oncology BranchNational Cancer Institute, National Institutes of HealthBethesdaUSA
| | - Hope Miller
- Neuro‐Oncology BranchNational Cancer Institute, National Institutes of HealthBethesdaUSA
| | - Elizabeth Vera
- Office of Patient‐Centered Outcomes ResearchNational Cancer Institute, National Institutes of HealthBethesdaUSA
| | | | - Brayden Chavis
- Neuro‐Oncology BranchNational Cancer Institute, National Institutes of HealthBethesdaUSA
| | - Anna Choi
- Neuro‐Oncology BranchNational Cancer Institute, National Institutes of HealthBethesdaUSA
| | - Ewa Grajkowska
- Neuro‐Oncology BranchNational Cancer Institute, National Institutes of HealthBethesdaUSA
| | - Tricia Kunst
- Neuro‐Oncology BranchNational Cancer Institute, National Institutes of HealthBethesdaUSA
| | - Morgan Johnson
- Neuro‐Oncology BranchNational Cancer Institute, National Institutes of HealthBethesdaUSA
| | - Zuena Karim
- Neuro‐Oncology BranchNational Cancer Institute, National Institutes of HealthBethesdaUSA
| | - Bennett McIver
- Neuro‐Oncology BranchNational Cancer Institute, National Institutes of HealthBethesdaUSA
| | - Madhura Managoli
- Neuro‐Oncology BranchNational Cancer Institute, National Institutes of HealthBethesdaUSA
| | - Jennifer Reyes
- Neuro‐Oncology BranchNational Cancer Institute, National Institutes of HealthBethesdaUSA
| | - Terri S. Armstrong
- Neuro‐Oncology BranchNational Cancer Institute, National Institutes of HealthBethesdaUSA
- Office of Patient‐Centered Outcomes ResearchNational Cancer Institute, National Institutes of HealthBethesdaUSA
| | - Amanda L. King
- Office of Patient‐Centered Outcomes ResearchNational Cancer Institute, National Institutes of HealthBethesdaUSA
| |
Collapse
|
3
|
Chen Y, Yu W, Huang Y, Jiang Z, Deng J, Qi Y. Causal associations between sleep traits, sleep disorders, and glioblastoma: a two-sample bidirectional Mendelian randomization study. J Neurophysiol 2025; 133:513-521. [PMID: 39740798 DOI: 10.1152/jn.00338.2024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2024] [Revised: 12/18/2024] [Accepted: 12/19/2024] [Indexed: 01/02/2025] Open
Abstract
Glioblastoma (GBM), a highly aggressive brain tumor predominantly affecting individuals over 40, often co-occurs with sleep disorders. However, the causal relationship remains unclear. This study employed a bidirectional Mendelian randomization (MR) approach to investigate the causal links between sleep traits/disorders and GBM. Sleep trait and disorder data were obtained from the IEU Open GWAS Project, while GBM data came from the Finn cohort. Primary analysis utilized the inverse-variance weighted (IVW) method, complemented by MR-Egger, weighted median, and weighted mode methods. MR pleiotropy residual sum and outlier (MR-PRESSO) was applied to detect potential outliers, and MR-Egger regression explored horizontal pleiotropy, with Cochran's Q test assessing heterogeneity. IVW analysis indicated a significant negative association between sleep duration and GBM risk [odds ratio (OR) = 0.13; 95% confidence interval (CI) = 0.02-0.80; P = 0.027). Conversely, GBM was positively associated with evening chronotype (OR = 1.0094; 95% CI = 1.0034-1.0154; P = 0.002). No significant associations were found for other sleep traits or disorders. Midday napping showed potential pleiotropy, and significant heterogeneity was noted in the reverse analysis. MR-PRESSO identified no outliers. Shorter sleep duration may elevate GBM risk, and GBM might influence circadian preference toward eveningness. Further studies are warranted to validate these findings.NEW & NOTEWORTHY This study employs a bidirectional Mendelian randomization approach to explore the causal relationship between various sleep traits, sleep disorders, and glioblastoma (GBM). We found that shorter sleep duration may increase GBM risk, while GBM may shift individuals toward an evening chronotype. No significant relationships were observed for other sleep traits or any of the sleep disorders. These findings illuminate the complex interplay between sleep and GBM, highlighting the need for further investigation into their correlations.
Collapse
Affiliation(s)
- Yuan Chen
- Department of Neurosurgery, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China
| | - Wenjun Yu
- Department of Neurosurgery, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China
| | - Yang Huang
- Department of Neurosurgery, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China
| | - Zijuan Jiang
- Department of Neurosurgery, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China
| | - Juan Deng
- Department of Neurosurgery, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China
| | - Yujuan Qi
- Department of Neurosurgery, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, Jiangsu Province, China
| |
Collapse
|
4
|
Pascoe M, Byrne E, King A, Cooper D, Foldvary-Schaefer N, Mehra R, Lathia J, Gilbert MR, Armstrong TS. Sleep disorders associated with cranial radiation-A systematic review. Neuro Oncol 2025; 27:63-76. [PMID: 39468721 PMCID: PMC11726243 DOI: 10.1093/neuonc/noae174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2024] [Indexed: 10/30/2024] Open
Abstract
BACKGROUND Radiation is the standard-of-care treatment for primary brain tumors (PBTs) but may have profound effects on sleep that have not yet been fully characterized. This systematic review aims to further our understanding of radiation therapy on the risk of development of sleep disorders in patients with PBTs, as well as potential opportunities for prevention and treatment. METHODS A systematic search of PubMed, Embase, and Web of Science was performed (last Jan 2024) with predefined inclusion (PBT patients, radiation therapy, somnolence/circadian disruption) and exclusion (reviews/abstracts/cases/chapters, non-PBT cancer, lack of radiation) criteria, yielding 267 papers initially and 38 studies included. Data extraction and analysis (descriptive statistics, individual study summary) focused on the incidence of sleep disturbances, radiation types/doses, and pharmacologic interventions. Risk of bias assessment was conducted with the Effective Public Health Practice Project's Quality Assessment Tool for Quantitative Studies. RESULTS The included 38 studies (n = 2948 patients) demonstrated a high incidence of sleep disturbances in patients with PBTs throughout radiation therapy, but primarily from the end of radiation to 6 months after. Sleep symptoms were associated with radiation (dose-dependent), and pharmacotherapies were helpful in patients with formal sleep disorder diagnoses. Terminology and incidence reporting of sleep symptoms are inconsistent, and many studies had a high risk of bias. CONCLUSIONS This systematic review highlights the ongoing challenges with sleep symptoms/disorders related to cranial irradiation treatment in the primary brain tumor population. Further investigations on the interconnectedness of sleep disturbance constructs and possible pharmacotherapies to alleviate symptoms are warranted.
Collapse
Affiliation(s)
- Maeve Pascoe
- Neuro-Oncology Branch, Center for Cancer Research, National Institutes of Health Neuro-oncology Branch, Bethesda, Maryland, USA
| | - Emma Byrne
- Neuro-Oncology Branch, Center for Cancer Research, National Institutes of Health Neuro-oncology Branch, Bethesda, Maryland, USA
| | - Amanda King
- Neuro-Oncology Branch, Center for Cancer Research, National Institutes of Health Neuro-oncology Branch, Bethesda, Maryland, USA
| | - Diane Cooper
- Division of Library Services, National Institutes of Health, National Institutes of Health Library, Bethesda, Maryland, USA
| | - Nancy Foldvary-Schaefer
- Lerner Research Institute and Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA
| | - Reena Mehra
- Lerner Research Institute and Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA
| | - Justin Lathia
- Lerner Research Institute and Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA
| | - Mark R Gilbert
- Neuro-Oncology Branch, Center for Cancer Research, National Institutes of Health Neuro-oncology Branch, Bethesda, Maryland, USA
| | - Terri S Armstrong
- Neuro-Oncology Branch, Center for Cancer Research, National Institutes of Health Neuro-oncology Branch, Bethesda, Maryland, USA
| |
Collapse
|
5
|
O'Donovan B, Malone A, Horgan F, Bennett K. A scoping review protocol of the rehabilitation needs of people with brain tumours. HRB Open Res 2024; 6:45. [PMID: 38304095 PMCID: PMC10831223 DOI: 10.12688/hrbopenres.13773.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/16/2024] [Indexed: 02/03/2024] Open
Abstract
Background Every year 480 people are diagnosed with a primary brain tumour in Ireland. Brain tumours can vary in type, location, treatment, and progression but neurological impairments are a consistent feature. Such neurological disability creates significant symptom burden that can seriously impact peoples' functional ability and quality of life. Rehabilitation can improve functional prognosis (motor and cognitive) and quality of life in people with brain tumours. However, research and experience consistently show that people with brain tumours can have difficulties accessing rehabilitation services. Our scoping review will investigate the research evidence concerning the rehabilitation needs of people with brain tumours. Methods The scoping review will be conducted in line with Preferred Reporting Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) reporting guidelines. Relevant databases (PubMed, Embase, CINAHL+, PsychINFO, PEDro) and grey literature sources will be searched. Publications relating to international rehabilitation practices will be included. A data extraction table will be created to facilitate narrative synthesis of the results. Conclusions This scoping review will examine the scope of the literature on the rehabilitation needs of people with brain tumours. The findings will inform a research project entitled "Surgery, radiotherapy, chemotherapy, but now what? Exploring the rehabilitation needs of people with brain tumours in Ireland". An article reporting the results of the scoping review will be submitted to a scientific journal and presented at relevant national and international conferences.
Collapse
Affiliation(s)
- B. O'Donovan
- School of Population Health, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| | - A. Malone
- School of Physiotherapy, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| | - F. Horgan
- School of Physiotherapy, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| | - K. Bennett
- School of Population Health, RCSI University of Medicine and Health Sciences, Dublin, Ireland
| |
Collapse
|
6
|
Shirokov A, Blokhina I, Fedosov I, Ilyukov E, Terskov A, Myagkov D, Tuktarov D, Tzoy M, Adushkina V, Zlatogosrkaya D, Evsyukova A, Telnova V, Dubrovsky A, Dmitrenko A, Manzhaeva M, Krupnova V, Tuzhilkin M, Elezarova I, Navolokin N, Saranceva E, Iskra T, Lykova E, Semyachkina-Glushkovskaya O. Different Effects of Phototherapy for Rat Glioma during Sleep and Wakefulness. Biomedicines 2024; 12:262. [PMID: 38397864 PMCID: PMC10886766 DOI: 10.3390/biomedicines12020262] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2023] [Revised: 01/17/2024] [Accepted: 01/18/2024] [Indexed: 02/25/2024] Open
Abstract
There is an association between sleep quality and glioma-specific outcomes, including survival. The critical role of sleep in survival among subjects with glioma may be due to sleep-induced activation of brain drainage (BD), that is dramatically suppressed in subjects with glioma. Emerging evidence demonstrates that photobiomodulation (PBM) is an effective technology for both the stimulation of BD and as an add-on therapy for glioma. Emerging evidence suggests that PBM during sleep stimulates BD more strongly than when awake. In this study on male Wistar rats, we clearly demonstrate that the PBM course during sleep vs. when awake more effectively suppresses glioma growth and increases survival compared with the control. The study of the mechanisms of this phenomenon revealed stronger effects of the PBM course in sleeping vs. awake rats on the stimulation of BD and an immune response against glioma, including an increase in the number of CD8+ in glioma cells, activation of apoptosis, and blockage of the proliferation of glioma cells. Our new technology for sleep-phototherapy opens a new strategy to improve the quality of medical care for patients with brain cancer, using promising smart-sleep and non-invasive approaches of glioma treatment.
Collapse
Affiliation(s)
- Alexander Shirokov
- Institute of Biochemistry and Physiology of Plants and Microorganisms, Saratov Scientific Centre of the Russian Academy of Sciences, Prospekt Entuziastov 13, 410049 Saratov, Russia
- Department of Biology, Saratov State University, Astrakhanskaya Str. 83, 410012 Saratov, Russia; (I.B.); (A.T.); (V.A.); (D.Z.); (A.E.); (V.T.); (A.D.); (M.M.); (V.K.); (M.T.); (I.E.); (N.N.); (E.S.); (T.I.); (E.L.)
| | - Inna Blokhina
- Department of Biology, Saratov State University, Astrakhanskaya Str. 83, 410012 Saratov, Russia; (I.B.); (A.T.); (V.A.); (D.Z.); (A.E.); (V.T.); (A.D.); (M.M.); (V.K.); (M.T.); (I.E.); (N.N.); (E.S.); (T.I.); (E.L.)
| | - Ivan Fedosov
- Physics Department, Saratov State University, Astrakhanskaya Str. 83, 410012 Saratov, Russia; (I.F.); (E.I.); (D.M.); (D.T.); (M.T.); (A.D.)
| | - Egor Ilyukov
- Physics Department, Saratov State University, Astrakhanskaya Str. 83, 410012 Saratov, Russia; (I.F.); (E.I.); (D.M.); (D.T.); (M.T.); (A.D.)
| | - Andrey Terskov
- Department of Biology, Saratov State University, Astrakhanskaya Str. 83, 410012 Saratov, Russia; (I.B.); (A.T.); (V.A.); (D.Z.); (A.E.); (V.T.); (A.D.); (M.M.); (V.K.); (M.T.); (I.E.); (N.N.); (E.S.); (T.I.); (E.L.)
| | - Dmitry Myagkov
- Physics Department, Saratov State University, Astrakhanskaya Str. 83, 410012 Saratov, Russia; (I.F.); (E.I.); (D.M.); (D.T.); (M.T.); (A.D.)
| | - Dmitry Tuktarov
- Physics Department, Saratov State University, Astrakhanskaya Str. 83, 410012 Saratov, Russia; (I.F.); (E.I.); (D.M.); (D.T.); (M.T.); (A.D.)
| | - Maria Tzoy
- Physics Department, Saratov State University, Astrakhanskaya Str. 83, 410012 Saratov, Russia; (I.F.); (E.I.); (D.M.); (D.T.); (M.T.); (A.D.)
| | - Viktoria Adushkina
- Department of Biology, Saratov State University, Astrakhanskaya Str. 83, 410012 Saratov, Russia; (I.B.); (A.T.); (V.A.); (D.Z.); (A.E.); (V.T.); (A.D.); (M.M.); (V.K.); (M.T.); (I.E.); (N.N.); (E.S.); (T.I.); (E.L.)
| | - Daria Zlatogosrkaya
- Department of Biology, Saratov State University, Astrakhanskaya Str. 83, 410012 Saratov, Russia; (I.B.); (A.T.); (V.A.); (D.Z.); (A.E.); (V.T.); (A.D.); (M.M.); (V.K.); (M.T.); (I.E.); (N.N.); (E.S.); (T.I.); (E.L.)
| | - Arina Evsyukova
- Department of Biology, Saratov State University, Astrakhanskaya Str. 83, 410012 Saratov, Russia; (I.B.); (A.T.); (V.A.); (D.Z.); (A.E.); (V.T.); (A.D.); (M.M.); (V.K.); (M.T.); (I.E.); (N.N.); (E.S.); (T.I.); (E.L.)
| | - Valeria Telnova
- Department of Biology, Saratov State University, Astrakhanskaya Str. 83, 410012 Saratov, Russia; (I.B.); (A.T.); (V.A.); (D.Z.); (A.E.); (V.T.); (A.D.); (M.M.); (V.K.); (M.T.); (I.E.); (N.N.); (E.S.); (T.I.); (E.L.)
| | - Alexander Dubrovsky
- Physics Department, Saratov State University, Astrakhanskaya Str. 83, 410012 Saratov, Russia; (I.F.); (E.I.); (D.M.); (D.T.); (M.T.); (A.D.)
| | - Alexander Dmitrenko
- Department of Biology, Saratov State University, Astrakhanskaya Str. 83, 410012 Saratov, Russia; (I.B.); (A.T.); (V.A.); (D.Z.); (A.E.); (V.T.); (A.D.); (M.M.); (V.K.); (M.T.); (I.E.); (N.N.); (E.S.); (T.I.); (E.L.)
| | - Maria Manzhaeva
- Department of Biology, Saratov State University, Astrakhanskaya Str. 83, 410012 Saratov, Russia; (I.B.); (A.T.); (V.A.); (D.Z.); (A.E.); (V.T.); (A.D.); (M.M.); (V.K.); (M.T.); (I.E.); (N.N.); (E.S.); (T.I.); (E.L.)
| | - Valeria Krupnova
- Department of Biology, Saratov State University, Astrakhanskaya Str. 83, 410012 Saratov, Russia; (I.B.); (A.T.); (V.A.); (D.Z.); (A.E.); (V.T.); (A.D.); (M.M.); (V.K.); (M.T.); (I.E.); (N.N.); (E.S.); (T.I.); (E.L.)
| | - Matvey Tuzhilkin
- Department of Biology, Saratov State University, Astrakhanskaya Str. 83, 410012 Saratov, Russia; (I.B.); (A.T.); (V.A.); (D.Z.); (A.E.); (V.T.); (A.D.); (M.M.); (V.K.); (M.T.); (I.E.); (N.N.); (E.S.); (T.I.); (E.L.)
| | - Inna Elezarova
- Department of Biology, Saratov State University, Astrakhanskaya Str. 83, 410012 Saratov, Russia; (I.B.); (A.T.); (V.A.); (D.Z.); (A.E.); (V.T.); (A.D.); (M.M.); (V.K.); (M.T.); (I.E.); (N.N.); (E.S.); (T.I.); (E.L.)
| | - Nikita Navolokin
- Department of Biology, Saratov State University, Astrakhanskaya Str. 83, 410012 Saratov, Russia; (I.B.); (A.T.); (V.A.); (D.Z.); (A.E.); (V.T.); (A.D.); (M.M.); (V.K.); (M.T.); (I.E.); (N.N.); (E.S.); (T.I.); (E.L.)
- Department of Pathological Anatomy, Saratov Medical State University, Bolshaya Kazachaya Str. 112, 410012 Saratov, Russia
| | - Elena Saranceva
- Department of Biology, Saratov State University, Astrakhanskaya Str. 83, 410012 Saratov, Russia; (I.B.); (A.T.); (V.A.); (D.Z.); (A.E.); (V.T.); (A.D.); (M.M.); (V.K.); (M.T.); (I.E.); (N.N.); (E.S.); (T.I.); (E.L.)
| | - Tatyana Iskra
- Department of Biology, Saratov State University, Astrakhanskaya Str. 83, 410012 Saratov, Russia; (I.B.); (A.T.); (V.A.); (D.Z.); (A.E.); (V.T.); (A.D.); (M.M.); (V.K.); (M.T.); (I.E.); (N.N.); (E.S.); (T.I.); (E.L.)
| | - Ekaterina Lykova
- Department of Biology, Saratov State University, Astrakhanskaya Str. 83, 410012 Saratov, Russia; (I.B.); (A.T.); (V.A.); (D.Z.); (A.E.); (V.T.); (A.D.); (M.M.); (V.K.); (M.T.); (I.E.); (N.N.); (E.S.); (T.I.); (E.L.)
| | - Oxana Semyachkina-Glushkovskaya
- Department of Biology, Saratov State University, Astrakhanskaya Str. 83, 410012 Saratov, Russia; (I.B.); (A.T.); (V.A.); (D.Z.); (A.E.); (V.T.); (A.D.); (M.M.); (V.K.); (M.T.); (I.E.); (N.N.); (E.S.); (T.I.); (E.L.)
- Physics Department, Humboldt University, Newtonstrasse 15, 12489 Berlin, Germany
| |
Collapse
|
7
|
Amidi A, Haldbo-Classen L, Kallehauge JF, Wu LM, Zachariae R, Lassen-Ramshad Y, Lukacova S, Høyer M. Radiation dose to sleep-relevant brain structures linked to impaired sleep quality in primary brain tumor patients. Acta Oncol 2023; 62:1520-1525. [PMID: 37688522 DOI: 10.1080/0284186x.2023.2249219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2023] [Accepted: 08/10/2023] [Indexed: 09/11/2023]
Affiliation(s)
- Ali Amidi
- Department of Psychology & Behavioural Sciences, Sleep and Circadian Psychology Research Group, Aarhus University, Aarhus, Denmark
- Department of Oncology, Unit for Psycho-oncology & Health Psychology, Aarhus University Hospital, Aarhus, Denmark
| | | | - Jesper F Kallehauge
- Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark
| | - Lisa M Wu
- Department of Psychology & Behavioural Sciences, Sleep and Circadian Psychology Research Group, Aarhus University, Aarhus, Denmark
- Department of Oncology, Unit for Psycho-oncology & Health Psychology, Aarhus University Hospital, Aarhus, Denmark
- Department of Psychology, Reykjavik University, Reykjavik, Iceland
| | - Robert Zachariae
- Department of Psychology & Behavioural Sciences, Sleep and Circadian Psychology Research Group, Aarhus University, Aarhus, Denmark
- Department of Oncology, Unit for Psycho-oncology & Health Psychology, Aarhus University Hospital, Aarhus, Denmark
| | | | - Slavka Lukacova
- Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
| | - Morten Høyer
- Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark
| |
Collapse
|